6FV.F SOFTOX SOLUTIONS NK 002

Healthcare Biotechnology Frankfurt Exchange
0.0100 EUR
Close of Nov 11, 2026
0.0030 0.0500
Market cap
EUR 27.1M
P/E
-
P/B
12.46x
ROE
-47.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 6FV.F undervalued?

Graham number

The Graham number of SOFTOX SOLUTIONS NK 002 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

SOFTOX SOLUTIONS NK 002 fundamental analysis

No fundamental analysis for SOFTOX SOLUTIONS NK 002 yet.

SOFTOX SOLUTIONS NK 002 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About SOFTOX SOLUTIONS NK 002

SoftOx Solutions AS, together with its subsidiaries, operates as a clinical-stage pharmaceutical company that anti-infective therapy for airway infections in Norway. The company develops SIS-03, a lead clinical program that is in phase 2a to treatment of chronic airway infections. It also developing pan antimicrobial pharmaceuticals targeting bacteria, viruses, yeast, spores, and fungi. SoftOx Solutions AS was founded in 2012 and is based in Lysaker, Norway.

Full company profile